Logo

Directif Partners with Epidauros to Market Its LabChip for Clinical Diagnostics

Mar 23, 2005

NEW YORK, March 23 (GenomeWeb News) - Directif GmbH and Epidauros Biotechnology have signed a co-development and co-marketing agreement for Directif's LabChip technology, the firms said today.

 

Epidauros, a provider of pharmacogenetic assays and services, will partner with Directif, a subsidiary of November AG based in Erlangen, Germany, to create "client-specific" applications for the LabChip technology, which offers automated analysis of nucleic acids for clinical diagnostic applications.

 

Bernried, Germany-based Epidauros said that it will market the LabChip to its established clientele of international pharmaceutical companies. Epidauros licensed a genetic polymorphism to Roche in November 2004 for use in its AmpliChip CYP450 test.

 

Financial details of the collaboration were not discussed.

Breaking News
The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.